Drug Profile
Research programme: anticancer therapeutics - AstraZeneca/University of Texas M.D. Anderson Cancer Center
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator AstraZeneca; University of Texas M. D. Anderson Cancer Center
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 28 Mar 2008 Preclinical development is ongoing
- 12 Jan 2006 Preclinical trials in Cancer in USA (unspecified route)